Clinical variants and the nature of obstruction
Chronic obstructive bronchitis and emphysema usually develop concomitantly, especially in advanced stages of the disease. For accurate differential diagnosis, it is extremely important to clinically identify the predominant component, the so-called phenotype. Traditionally, two polar variants are distinguished: bronchitic and emphysematous. Understanding the differences between them is based on assessing changes in terminal bronchioles, alveoli, and pulmonary capillaries.
Bronchitic variant ("blue bloaters")
The morphological basis of this phenotype is irreversible inflammatory and fibrotic changes in small bronchi. The leading etiological factor sustaining progression is cigarette smoking. Due to frequent cyanosis and pronounced peripheral edema, such patients are clinically referred to as "blue bloaters" (from English blue bloaters).
In this variant, the terminal bronchioles narrow, but the alveoli themselves remain morphologically intact. However, their ventilation is severely impaired, which triggers a severe pathogenetic chain of complications (Cor pulmonale):
- Inflammatory edema of the terminal bronchiole mucosa develops.
- Pronounced alveolar hypoventilation develops.
- Blood gas composition is impaired: hypoxemia (decrease in $P_{O_2}$) and hypercapnia (increase in $P_{CO_2}$) occur.
- In response to hypoxia, the Euler-Liljestrand reflex is triggered — vasoconstriction of alveolar capillaries, leading to pulmonary hypertension.
- Chronic cor pulmonale develops.
- Systemic circulatory decompensation occurs, causing peripheral edema.
Emphysematous variant ("pink puffers")
This variant differs fundamentally in its pathophysiology. Destruction of interalveolar septa occurs with the formation of large cavities (increased alveolar volume) and destruction of alveolar capillaries (reduction of the vascular bed).
The clinical and pathogenetic picture of patients with predominant emphysema:
- Appearance: cyanosis is usually absent (hence the term "pink"). The dominant symptom is severe expiratory dyspnea ("puffers").
- Mechanism of obstruction: loss of lung elastic recoil leads to expiratory bronchial collapse (airway collapse during expiration).
- Gas exchange features: the key difference from the bronchitic type is the absence of blood shunting. Ventilation-perfusion ratios in the remaining areas are preserved. Blood gas composition remains constant for a long time due to compensation.
The main etiological factor here is also smoking, but pollutants and genetics play an important additional role.
Predisposing factors for COPD development
A number of exogenous and endogenous risk factors contribute to the development of COPD:
- Smoking (active and passive): causes impaired mucociliary clearance (ciliated epithelium function), suppresses alveolar macrophage activity, and provokes mucous gland hyperplasia (hypersecretion) and bronchospasm.
- Atmospheric air pollution: inhalation of acid vapors, irritant gases (sulfur dioxide), as well as organic and inorganic dust.
- Infectious agents: viruses, bacteria, and mycoplasmas maintain the chronic inflammatory process.
- Genetic factors: $\alpha_1$-antitrypsin deficiency. This leads to impaired inactivation of neutrophil proteolytic enzymes during inflammation, resulting in the destruction of the lung tissue itself.
Briefly: answers to topical questions
What are the spirometric criteria for diagnosing COPD?
The main spirometric criterion for diagnosing COPD is a decrease in the post-bronchodilator Tiffeneau index below normal values.
- Tiffeneau-Pinelli / Gensler index — the ratio of forced expiratory volume in 1 second to forced vital capacity ($FEV_1/FVC$).
The diagnosis is confirmed if, after spirometry with a bronchodilator test, this indicator is less than 0.7. This criterion confirms the presence of expiratory airflow limitation and is the main method for documenting obstructive disorders.
Which groups of medications are used for basic COPD therapy?
Long-acting inhaled medications for obstructive diseases are used for basic COPD therapy.
The following drug groups and combinations are used:
- LABA — long-acting beta-agonists;
- LAMA — long-acting anticholinergics;
- LABA + LAMA;
- LABA + LAMA + ICS — inhaled corticosteroids as part of triple therapy.
Also, in stable COPD, short-acting bronchodilators are used on an as-needed basis only.
How is differential diagnosis between COPD and bronchial asthma performed?
Differential diagnosis between COPD and bronchial asthma (BA) is performed taking into account spirometry data with a bronchodilator and trial therapy with inhaled corticosteroids (ICS).
- Bronchodilator reversibility testing during spirometry does not reliably differentiate BA from COPD: in BA, significant reversibility of obstruction is not always present, while in COPD, 25–50% of patients exhibit significant reversibility.
- For adults, a sign of bronchial obstruction reversibility is an increase in $FEV_1$ by more than 12% and more than 200 ml.
- Trial ICS therapy: if it leads to normalization of pulmonary function, it is recommended to discard the COPD diagnosis in favor of BA.
- If ICS treatment does not lead to a significant change in lung function, a COPD diagnosis is more likely.
The ICS test is not absolute: a number of COPD patients may show a positive effect from ICS, and some BA patients may not experience improvement with ICS monotherapy.
What systemic complications are characteristic of COPD, apart from chronic cor pulmonale?
In addition to chronic cor pulmonale, COPD is characterized by systemic extra-pulmonary manifestations.
The main systemic effects include:
- systemic inflammation;
- cachexia;
- skeletal muscle dysfunction;
- osteoporosis;
- cardiovascular events;
- anemia;
- depression.
Risk factors for the development of these manifestations are hypoxemia, smoking, a sedentary lifestyle, and systemic inflammation.
To memorize clinical phenotypes: Bronchitis — Blue/pale cyanosis (edema, hypoxia, cor pulmonale). Emphysema — Expiratory dyspnea, absence of cyanosis ("pink" color, bronchial collapse).
Class and exam questions
What is the difference in obstruction mechanisms among various COPD phenotypes?
In the emphysematous phenotype, this is expiratory bronchial collapse due to the loss of lung elastic recoil. In the bronchitic phenotype, it is irreversible narrowing of the terminal bronchioles due to inflammatory and fibrotic changes.
What is the Euler-Liljestrand reflex and what is its role?
This is a compensatory spasm of alveolar capillaries in response to hypoxia (reduced oxygen). In chronic bronchitis, this reflex causes pulmonary hypertension and the development of cor pulmonale.
Why do "pink puffers" not develop cyanosis for a long time?
In the emphysematous phenotype, both alveoli and capillaries are destroyed, so blood shunting does not occur. Ventilation-perfusion balance is maintained, keeping gas composition normal.
What is the role of alpha-1 antitrypsin in the development of the disease?
This enzyme inactivates neutrophil proteolytic enzymes. In its genetic deficiency, these enzymes are not neutralized and begin to destroy lung tissue, leading to emphysema.
What else to study on this topic
- Mechanisms of impaired mucociliary clearance under prolonged exposure to tobacco smoke.
- The role of macrophages and neutrophil enzymes in the destruction of interalveolar septa.
- Stages of decompensation in chronic cor pulmonale.
- Differential diagnosis of obstructive bronchitis and severe bronchial asthma.
- Effects of hypoxemia and hypercapnia on systemic hemodynamics.
Master the entire topic in the "Propaedeutics" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Chronic Obstructive Pulmonary Disease" and 3,152 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 113 video lessons on the subject
Other topics in the "Respiratory System" section
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.